| Title |
Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
|
|---|---|
| Published in |
PLOS ONE, September 2011
|
| DOI | 10.1371/journal.pone.0023379 |
| Pubmed ID | |
| Authors |
Sandra L. Dabora, David Neal Franz, Stephen Ashwal, Arthur Sagalowsky, Francis J. DiMario, Daniel Miles, Drew Cutler, Darcy Krueger, Raul N. Uppot, Rahmin Rabenou, Susana Camposano, Jan Paolini, Fiona Fennessy, Nancy Lee, Chelsey Woodrum, Judith Manola, Judy Garber, Elizabeth A. Thiele |
| Abstract |
Tuberous sclerosis (TSC) related tumors are characterized by constitutively activated mTOR signaling due to mutations in TSC1 or TSC2. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 2% |
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 119 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 11% |
| Student > Master | 13 | 11% |
| Student > Ph. D. Student | 12 | 10% |
| Student > Doctoral Student | 12 | 10% |
| Student > Bachelor | 12 | 10% |
| Other | 30 | 24% |
| Unknown | 31 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 43% |
| Biochemistry, Genetics and Molecular Biology | 11 | 9% |
| Agricultural and Biological Sciences | 7 | 6% |
| Nursing and Health Professions | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 10 | 8% |
| Unknown | 35 | 28% |